Italia markets closed

FibroGen, Inc. (0IL8.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
11,93+0,93 (+8,45%)
Alla chiusura: 03:30PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    FibroGen to Participate at William Blair Biotech Focus Conference 2022

    SAN FRANCISCO, July 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the William Blair Biotech Focus Conference 2022 taking place the week of July 11, 2022. A webcast of the event will be available Monday, July 11 at 9:00am ET on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. The replay will be available for approximately 30 days. About Fib

  • GlobeNewswire

    FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy

    - 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for LELANTOS-2, a Phase 3 clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy (DMD). “We are very pleased to complete enrollment of our second Phase 3 study of pamrevlumab in patients with DMD,” said Mark Eisner, M.D, M.P.H, Chief Medical Officer, FibroGen. “Ped

  • GlobeNewswire

    FibroGen to Present at Jefferies Healthcare Conference

    SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT. A live audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investors webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen FibroGen, Inc. is a biopharmaceu